These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26295044)

  • 21. Neuroinflammation in Parkinson's disease and its potential as therapeutic target.
    Wang Q; Liu Y; Zhou J
    Transl Neurodegener; 2015; 4():19. PubMed ID: 26464797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies.
    Lu M; Hu G
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):577-85. PubMed ID: 22126374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
    Collins LM; Toulouse A; Connor TJ; Nolan YM
    Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease.
    Sita G; Hrelia P; Tarozzi A; Morroni F
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
    Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
    Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of microglia on the pathogenesis of Parkinson's disease.
    Long-Smith CM; Sullivan AM; Nolan YM
    Prog Neurobiol; 2009 Nov; 89(3):277-87. PubMed ID: 19686799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
    Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
    Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.
    Lu L; Li F; Wang X
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):232-40. PubMed ID: 20015029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells.
    González H; Contreras F; Pacheco R
    J Neuroimmune Pharmacol; 2015 Dec; 10(4):561-75. PubMed ID: 26018603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroinflammation in Parkinson's disease.
    Hirsch EC; Vyas S; Hunot S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
    Renaud J; Nabavi SF; Daglia M; Nabavi SM; Martinoli MG
    Rejuvenation Res; 2015 Jun; 18(3):257-69. PubMed ID: 25625827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
    Clark LF; Kodadek T
    ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurodegeneration and inflammation in Parkinson's disease.
    Phani S; Loike JD; Przedborski S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S207-9. PubMed ID: 22166436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Saad HM; Batiha GE
    Inflammopharmacology; 2023 Apr; 31(2):673-688. PubMed ID: 36961665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation as a causative factor in the aetiology of Parkinson's disease.
    Whitton PS
    Br J Pharmacol; 2007 Apr; 150(8):963-76. PubMed ID: 17339843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.